About: Performance & Quality Evaluation of Marketed COVID-19 RNA Detection Kits

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Performance & Quality Evaluation of Marketed COVID-19 RNA Detection Kits Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Performance & Quality Evaluation of Marketed COVID-19 RNA Detection Kits
Creator	Chen, Xiangyong Jiang, Jianhao Jiang, Zhuopu Kapitula, David Lin, Claudia Zhu, Jing
Source	MedRxiv
abstract	Compared to other coronaviruses, COVID-19 has a longer incubation period and features asymptomatic infection at a high rate (>25%). Therefore, early detection of infection is the key to early isolation and treatment. Direct detection of the virus itself has advantages over indirect detection. Currently, the most sensitive and commercially validated method for COVID-19 testing is RT-qPCR, designed to detect amplified virus-specific RNA. Reliable testing has proven to be a bottleneck in early diagnosis of virus infection in all countries dealing with the pandemic. Significant performance and quality issues with available testing kits have caused confusion and serious health risks. In order to provide better understanding of the Quality and performance of COVID-19 RNA detection kits on the market, we designed a system to evaluate the specificity (quantitation), sensitivity (LOD) and robustness of the kits using positive RNA and pseudovirus controls based on COVID-19 genomic sequence. We evaluated 8 Nucleic Acid qPCR Kits approved in China, some of which are also approved in the US and EU. Our study showed that half of these 8 kits lack 1:1 linear relationship for virus RNA copy: qPCR signal. Of the 4 with linear response, 2 demonstrated sensitivity at 1 Copy viral RNA/Reaction, suitable for early detection of virus infection. Furthermore, we established the best RNA extraction, handling and qPCR procedures allowing highly sensitive and consistent performance using BGI qPCR kits. Our study provides an effective method to assess and compare performance quality of all COVID-19 nucleic acid testing kits, globally.
has issue date	2020-05-01(xsd:dateTime)
bibo:doi	10.1101/2020.04.25.20080002
has license	medrxiv
sha1sum (hex)	2e5a0bb1180a893dcf76a4e55f4d479ef7933135
schema:url	https://doi.org/10.1101/2020.04.25.20080002
resource representing a document's title	Performance & Quality Evaluation of Marketed COVID-19 RNA Detection Kits
resource representing a document's body	covid:2e5a0bb1180a893dcf76a4e55f4d479ef7933135#body_text
is schema:about of	named entity 'infection' named entity 'Copy' named entity 'indirect' named entity 'risks' named entity 'sensitive' named entity 'performance' named entity 'Performance' named entity 'PROVEN' named entity 'SIGNAL' named entity 'RELIABLE' named entity 'PSEUDOVIRUS' named entity 'HALF' named entity 'RT-QPCR' named entity 'TO PROVIDE' named entity 'VALIDATED' named entity 'TO DETECT' named entity 'DEMONSTRATED' named entity 'EARLY DIAGNOSIS' named entity 'EFFECTIVE' named entity 'BEST' named entity 'VIRAL RNA' named entity 'QPCR' named entity 'ESTABLISHED' named entity 'qPCR' named entity 'specificity' named entity 'virus' named entity 'confusion' named entity 'China' named entity 'RNA' named entity 'kits' named entity 'linear relationship' named entity 'based' named entity 'signal' named entity 'order' named entity 'early' named entity 'commercially' named entity 'RNA' named entity 'virus-specific' named entity 'caused' named entity 'viral' named entity 'performance' named entity 'COVID-19 testing' named entity 'RNA' named entity 'qPCR' named entity 'testing kits' named entity 'COVID-19' named entity 'LOD' named entity 'COVID-19' named entity 'quantitation' named entity 'linear relationship' named entity 'COVID-19' named entity 'nucleic acid testing' named entity 'COVID-19' named entity 'COVID' named entity 'nCoV' named entity 'Nucleocapsid' named entity 'copy number' named entity 'Carlsbad, CA' named entity 'oropharyngeal' named entity 'epidemic' named entity 'qPCR' named entity 'medRxiv' named entity 'gene' named entity 'Applied Biosystems' named entity 'preprint' named entity 'Thermo Scientific' named entity 'Thermo Scientific' named entity 'gene' named entity 'primers' named entity 'COVID-19' named entity 'Carlsbad, CA' named entity 'LOD' named entity 'Copy number' named entity 'COVID' named entity 'viruses' named entity 'Real-Time PCR' named entity 'fluorescence' named entity 'RT-PCR test' named entity 'IVD' named entity 'China'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software